December 18, 2002 Flamel Technologies announces receipt of $1.5 million milestone payment from GlaxoSmithKline for a sachet formulation of controlled release Augmentin®

October 22, 2002 Flamel Technologies announces third quarter earnings of $0.15 per share; increase in cash position to $14.6 million

September 19, 2002 Flamel Technologies announces receipt of $4 million milestone payment from Servier Monde

July 25, 2002 Flamel Technologies announces breakeven quarterly results based on operating achievement; increase in cash position to $11.9 million

July 8, 2002 Flamel Technologies announces license agreement with GlaxoSmithKline for sachet formulation of controlled-release Augmentin®

April 29, 2002 Flamel Technologies announces first quarter results, showing a net profit of $ 0.07 per share

March 12, 2002 Flamel Technologies announces fourth quarter and year-end results: 2001 loss per share narrows to $0.8 per share

January 11, 2002 Flamel Technologies and Servier Monde announce Micropump® license agreement for ACE inhibitor, Flamel paid $3 million upon signing

January 11, 2002 Flamel Technologies announces termination of development agreement with Novo Nordisk for Basulin and reacquisition of rights